{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-223242","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.892047+00:00","generated_at":"2026-05-31T02:37:38.623802+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"FDA approves Zevra's MIPLYFFA for NPC; XOMA holds royalty on sales up to $52.6M milestones","bullets":["FDA approved MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) on Sept 20, 2024.","XOMA is entitled to a mid-single digit royalty on commercial sales of MIPLYFFA.","XOMA may receive up to $52.6 million (net) in milestone payments from Zevra.","MIPLYFFA is the sixth commercial asset in XOMA's royalty and milestone portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-223242","json":"https://secwatch.observer/filing/0001193125-24-223242.json","markdown":"https://secwatch.observer/filing/0001193125-24-223242.md","text":"https://secwatch.observer/filing/0001193125-24-223242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312524223242/0001193125-24-223242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312524223242/d836129d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:37:38.623802+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}